- Actueel
- Patiëntenzorg
-
Geneesmiddelen
- Apotheekbereiding
- Geneesmiddelentekorten
- Geneesmiddelvervalsing
- Handleiding Geneesmiddelsubstitutie
- PrEP-medicatie
- Recalls
- Vragen en antwoorden over melatonine
- Zelfzorgmiddelen
- Geneesmiddelengebruik en hitte
- Vragen en antwoorden over paracetamol
- Vragen en antwoorden over recall metformine
- KNMP-standpunten ‘Gereedmaken COVID-19-vaccins’ en ‘Uitwisseling vaccinatiegegevens COVID-19’
- Laaggeletterden en migranten
-
Medicatiebewaking
- Farmacogenetica
- Handleiding Zorg Registratie Systeem
- KNMP-richtlijn Medicatiebewaking
- KNMP-standpunt biosimilars en follow-on non-biological complex drugs (NBCD’s)
- KNMP-voorschrift Basisinstellingen AIS
- Medicatiebeoordeling
- Medisch Farmaceutische Beslisregels (MFB's)
- Morbide obesitas en bariatrische chirurgie
- Reden van voorschrijven en labwaarden
- Therapietrouw
- Medicatieoverdracht
- Samenwerking
- Toekomstvisie 2025
- Verminderde nierfunctie
- Kwetsbare ouderen
-
Geneesmiddelen
- Praktijkvoering
- Producten
- Professie
Miniaturized Metabolomics Phenotyping of Parkinson's disease
Farmacokinetiek en -dynamiek
My overall aim will be to establish new analytical methods and to optimise and miniaturise current platforms that can be utilised in the study of dopaminergic neurons (and astrocyte co-cultures) that are derived from induced pluripotent stem cells (iPSCs) for the study of oxidative stress associated with mitochondrial dysfunction. I am fortunate to have access to a range of clinical samples that will enable cross comparisons of any results obtained during the invitromodel experiments and provide vital information of which metabolites to target in mitochondrial dysfunction. Using the new methods and information obtained from the clinical studies,I will be able to translate these into a miniaturised platform coupled to the perfusion channel within the OrganoPlate®. All of the experiments conducted over the four-year period will enable the creation of a validated, miniaturised, automated high-throughput invitropharmacological screening device that can used for Parkinson’s disease and future application to other conditions.
Leiden
Cornelius Willacey
Prof. dr. T. Hankemeier
Dr. A.C. Harms
Vorige en volgende in Actueel promotieonderzoek:
Wnt/frizzled signaling in small airway remodelling in COPD Outcome studies in multiple myeloma patientsContact
Bezoekadres KNMP:
Alexanderstraat 11
2514 JL Den Haag
Postadres KNMP:
Postbus 30460
2500 GL Den Haag